Cough in Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology, and Market Forecast - 2034
특발성 폐섬유증(IPF)으로 인한 기침 시장은 예측 기간(2023-2034년) 동안 안정적인 성장을 보일 것으로 예상됩니다. 새로운 치료제의 출시로 인해 주요 7개국에서 IPF 기침 시장 규모가 확대될 것으로 예상됩니다. 주요 7개국에서 IPF 기침으로 진단받은 환자 중 약 51%는 미국에서 온 환자들입니다. 2022년에는 EU 4개국과 영국이 IPF 기침 진단 유병자 수 약 5만 5,000명을 차지했습니다.
주요 7개국에서 시장은 주로 신경조절제, 코르티코스테로이드 및 기타 면역조절제로 구성되어 있으며, 2022년 약 1억 5,400만 달러 시장을 창출했습니다.
만성 기침은 특발성 폐섬유증(IPF)에서 흔히 볼 수 있으며, 종종 초기 증상으로 나타나 환자의 생활에 큰 영향을 미칩니다. 이러한 지속적인 기침은 삶의 질 저하, 우울증과 불안감 증가, 생리적 장애 증가, 질병 진행과 관련이 있습니다. 만성 기침의 병태생리를 완전히 이해하는 것은 여전히 어려운 일이지만, 최근의 발전으로 그 다인자적 특성이 밝혀지고 있습니다.
IPF에서 만성 기침의 병태생리에는 점액 생성 및 제거의 변화, 폐조직의 구조적 변형, 기침 반사 증가 등 다양한 요인이 관여하며, IPF 환자의 경우 폐조직의 구조가 변화하여 점액을 효과적으로 생성하고 배출하는 능력이 손상될 수 있습니다. 또한, 기침 반사가 증가하면 IPF로 인한 기침이 지속될 수 있습니다. 기침 증상의 중증도는 전신 건강 상태의 저하와 관련이 있으며, 종종 질병의 진행을 나타냅니다.
IPF로 인한 기침을 진단하려면 임상 평가, 폐기능 검사(PFT), 고해상도 컴퓨터 단층 촬영(HRCT) 스캔을 포함한 종합적인 평가가 필요합니다. 경우에 따라 기관지 내시경 검사를 통해 기도를 검사하고 분석을 위한 샘플을 채취할 수도 있습니다. 다학제적 접근, 전문가 간의 협력, 다른 잠재적 원인을 배제하는 것이 필수적입니다.
현재 IPF로 인한 기침 치료제로 승인된 것은 없으며, IPF로 인한 기침 치료는 기침 반사를 억제하는 것과 IPF의 기저 병리를 특이적으로 표적으로 삼는 것으로 나뉩니다. 안타깝게도 기침 반사를 억제하는 치료법의 효과는 제한적입니다. 현재 치료법은 주로 신경 조절제, 부신피질 스테로이드 및 기타 면역 조절제로 분류되는 적응증 외 치료법으로, IPF의 치료 부족과 고빈도 기침은 환자의 삶의 질에 심각한 영향을 미칩니다.
7개 주요 국가의 특발성 폐섬유증(IPF)으로 인한 기침 시장 규모는 2022년 1억 5,400만 달러에 달했습니다. 미국이 2022년 시장 점유율이 61%에 육박하며 가장 큰 점유율을 차지했고, EU 4개국과 영국 시장 규모는 2022년 4,500만 달러에 달했습니다. 앞으로도 높은 CAGR로 확대될 것으로 예상됩니다.
이 보고서는 주요 7개국의 특발성 폐섬유증(IPF)으로 인한 기침 시장을 조사했으며, 시장 개요와 함께 역학, 환자 동향, 새로운 치료법, 2032년까지 시장 규모 예측, 의료 미충족 수요 등을 제공합니다.
목차
제1장 주요 인사이트
제2장 보고서 서론
제3장 특발성 폐 섬유증(IPF)에 의한 기침 시장 개요
제4장 IPF에 의한 기침 역학과 시장 조사 방법
제5장 IPF에 의한 기침 주요 요약
제6장 주요 이벤트
제7장 질환의 배경과 개요
- 서론
- IPF의 징후와 증상
- IPF에 의한 기침
- 만성 기침 병태생리학
- IPF에 의한 기침의 병태생리학
- IPF에 의한 기침의 메커니즘
- IPF에 의한 기침에 영향을 미치는 병존 질환
- 진단
- 치료
- IPF에 의한 기침 환자에 대한 일반적인 접근
제8장 역학과 환자수
- 주요 조사 결과
- IPF에 의한 기침 전제조건과 이론적 근거 : 주요 7개국
- 주요 7개국에서 IPF로 진단된 기침 이환 증례 합계
- 미국
- EU 4개국과 영국
- 일본
제9장 환자 동향
제10장 새로운 약제
제11장 IPF에 의한 기침 : 시장 분석
- 주요 조사 결과
- 주요 시장 예측의 전제조건
- 시장 전망
- 콘조인트 분석
- 주요 7개국의 IPF에 의한 기침 전체 시장 규모
- 주요 7개국의 IPF에 의한 기침 시장 규모, 치료법별
- 미국의 IPF에 의한 기침 시장 규모
- EU 4개국 및 영국의 IPF에 의한 기침 시장 규모
- 일본의 IPF에 의한 기침 시장 규모
제12장 주요 업계 리더의 견해
제13장 SWOT 분석
제14장 미충족 요구
제15장 시장 접근과 상환
제16장 부록
제17장 DelveInsight의 서비스 내용
제18장 면책사항
LSH
Key Highlights:
- The Cough in IPF market is projected to witness consistent growth throughout the forecast period (2023-2034). The market size of Cough in IPF in the 7MM is expected to increase, driven by the launch of emerging therapies.
- DelveInsight's analyst projects that among the total diagnosed prevalent cases of Cough in IPF in 7MM approximately 51% of cases were from the US. As per our estimations, in 2022, the EU4 and the UK accounted for nearly 55 thousand diagnosed prevalent cases of Cough in IPF.
- In the 7MM, the market mainly consisted of neuromodulators, corticosteroids, and other immunomodulatory agents which generated nearly USD 154 million in 2022.
- The total market size of the Cough in IPF treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, Orvepitant Maleate and Haduvio (nalbuphine).
DelveInsight's "Cough in Idiopathic pulmonary fibrosis (IPF) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Cough in IPF, historical and forecasted epidemiology and the Cough in IPF market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Cough in IPF market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Cough in IPF market size from 2020 to 2034. The report also covers current Cough in IPF treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered:
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study Period: 2020-2034.
Disease Understanding and Treatment Algorithm
Cough in IPF Overview
Chronic cough is prevalent in idiopathic pulmonary fibrosis (IPF), often presenting as the initial symptom and significantly impacting patients' lives. This persistent cough is associated with diminished quality of life, heightened rates of depression and anxiety, increased physiological impairment, and disease progression. While the complete understanding of its pathophysiology remains elusive, recent advancements shed light on its multifactorial nature.
The pathophysiology of chronic cough in IPF involves various factors, including alterations in mucous production and clearance, architectural distortion of lung tissues, and heightened sensitivity of the cough reflex. Patients with IPF may experience architectural changes in lung tissues, impairing their ability to produce and clear mucous effectively. Additionally, an increased sensitivity of the cough reflex contributes to the persistent nature of cough in IPF. The severity of cough symptoms is linked to a decline in overall health and is often indicative of disease progression.
Cough in IPF Diagnosis
The diagnosis of cough in IPF involves a comprehensive evaluation, including clinical assessment, pulmonary function tests (PFTs), and high-resolution computed tomography (HRCT) scans. In some cases, bronchoscopy may be utilized to examine the airways and collect samples for analysis. A multidisciplinary approach, collaboration among specialists, and the exclusion of other potential causes are integral.
Cough in IPF Treatment
Currently, there is no known approved treatment of cough in IPF. Therapies for cough in IPF can be divided into those that aim to suppress the cough reflex and those that specifically target the underlying pathology of IPF. Unfortunately, treatments aimed at suppressing the cough reflex have limited efficacy. The current treatment landscape consists of off-label therapies mainly classified as neuromodulating agents, corticosteroids, and other immunomodulatory agents. The lack of treatment and high frequency of cough in IPF severely impacts the quality of life of the patients.
Cough in IPF Epidemiology
As the market is derived using the patient-based model, the Cough in IPF epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of IPF and Total Diagnosed Prevalent Cases of Cough in IPF, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.
As per DelveInsight's estimations, the total diagnosed prevalent cases of Cough in IPF in the 7MM were approximately 148 thousand cases in 2022 and are projected to increase during the forecast period.
- The overall count of individuals diagnosed with IPF in the United States was approximately 95 thousand in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
- Among the 7MM, the US accounted for nearly 76 thousand diagnosed prevalent cases of Cough in IPF, and these cases are expected to increase during the forecast period (2023-2034).
- Among EU4 and the UK, the UK had the highest diagnosed prevalent population of Cough in IPF, with about 13 thousand cases, followed by France and Italy in 2022. On the other hand, Germany had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
- In Japan, there were around 17 thousand diagnosed prevalent cases of Cough in IPF in 2022. These cases are expected to increase at a significant CAGR.
Cough in IPF Drug Chapters
The drug chapter segment of the Cough in IPF report encloses a detailed analysis of Cough in IPF marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands Cough in IPF clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Emerging Drugs:
Orvepitant Maleate: NeRRe Therapeutics
Orvepitant Maleate, developed by NeRRe Therapeutics, is a novel, selective NK-1 receptor antagonist. It blocks substance P effects, reducing central neural hypersensitivity and addressing chronic cough through peripherally and centrally targeted mechanisms. After demonstrating proof of efficacy in patients with RCC or UCC, NeRRe is currently conducting Phase II trials to evaluate the effect of two doses of orvepitant in chronic cough with IPF.
Haduvio (nalbuphine ER): Trevi Therapeutics
Haduvio (nalbuphine ER) is under clinical development by Trevi Therapeutics and is currently in Phase II for cough in IPF treatment. Administered orally, it is an extended-release, mixed ?-opioid receptor agonist and µ-opioid receptor antagonist.
Note: Detailed emerging therapies assessment will be provided in the final report of Cough in IPF.
Cough in IPF Market Outlook
Cough, a predominant and distressing symptom in IPF, significantly compromises patients' quality of life, prompting a pressing need for effective interventions tailored to this aspect of the disease. Despite approved therapies for IPF, there is not an established treatment specifically targeting the associated cough.
Current therapeutic strategies for IPF-related cough fall into two categories: those suppressing the cough reflex and those targeting IPF pathology. Yet, agents like dextromethorphan and opioids exhibit limited efficacy and systemic side effects, hindering widespread use. Traditional IPF medications, pirfenidone and nintedanib, mainly focus on disease progression without extensive studies on managing IPF-related cough.
The IPF-related cough treatment market emphasizes the need for targeted therapies. Ongoing research in neuromodulating agents, immunomodulators, and behavior-based therapies holds promise, but comprehensive studies are needed to develop effective treatments, enhancing the quality of life for those affected by this challenging symptom.
The market for Cough in IPF is expected to experience positive growth with the approval of potential drugs like Orvepitant Maleate and Haduvio (nalbuphine ER).
- The Cough in IPF market's total size in the 7MM reached approximately USD 154 million in 2022. Projections indicate a substantial growth during the forecast period.
- Out of the 7MM, the United States dominated the market in 2022, representing the largest share at nearly 61%.
- In 2022, EU4 and the UK captured an estimated USD 45 million, which is anticipated to increase at a substantial CAGR. Among the European countries, the UK covered the largest market share in 2022, followed by France, Italy and Spain. Germany accounted for the least market in the same year.
- Japan alone represented approximately 10% of the total Cough in IPF market in 2022, projected to increase at a substantial CAGR during the study period.
- The total market size of the Cough in IPF treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments.
Cough in IPF Drugs Uptake
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, Haduvio (nalbuphine ER) in the US is expected to be launched by 2028.
Further detailed analysis of emerging therapies drug uptake in the report…
Cough in IPF Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Cough in IPF emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Cough in IPF evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Albert Einstein College of Medicine, New York; Keck School of Medicine, University of Southern California, Los Angeles; Ruhrlandklinik, University Hospital Essen, Essen, Germany; Louis Pradel Hospital, Hospices Civils de Lyon, France; University of Milano Bicocca, Italy; Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK; Graduate School of Medicine, Kyoto University, Kyoto, Japan, and others.
DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Cough in IPF market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Scope of the Report:
- The report covers a segment of key events, an executive summary, descriptive overview of Cough in IPF, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
- Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
- A detailed review of the Cough in IPF market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Cough in IPF market.
Cough in IPF Report Insights
- Patient Population
- Therapeutic Approaches
- Cough in IPF Pipeline Analysis
- Cough in IPF Market Size and Trends
- Existing and Future Market Opportunity
Cough in IPF Report Key Strengths
- 12 years Forecast
- The 7MM Coverage
- Cough in IPF Epidemiology Segmentation
- Key Cross Competition
- Conjoint Analysis
- Drugs Uptake and Key Market Forecast Assumptions
Cough in IPF Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Qualitative Analysis (SWOT and Conjoint Analysis)
Key Questions:
Market Insights
- What was the Cough in IPF total market size, the market size by therapies, and market share (%) distribution in 2020, and how would it all look in 2034? What are the contributing factors for this growth?
- What unmet needs are associated with the current treatment market of Cough in IPF?
- What are the patents of emerging therapies for Cough in IPF?
- Which drug is going to be the largest contributor by 2034?
- What are the pricing variations among different geographies for approved and off-label therapies?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights
- What are the disease risks, burdens, and unmet needs of Cough in IPF? What will be the growth opportunities across the 7MM concerning the patient population of Cough in IPF?
- What is the historical and forecasted Cough in IPF patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
- Why do only limited patients appear for diagnosis?
- Which country is more prevalent for Cough in IPF and why?
- What factors are affecting the diagnosis of the indication?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
- What are the current options for treating Cough in IPF? What are the current guidelines for treating Cough in IPF in the US and Europe?
- How many companies are developing therapies for treating Cough in IPF?
- How many emerging therapies are in the mid-stage and late stage of development for treating Cough in IPF?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
- What are the key designations that have been granted for the emerging therapies for Cough in IPF?
- Patient acceptability in terms of preferred treatment options as per real-world scenarios?
- What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
- What are the 7MM historical and forecasted markets of Cough in IPF?
Reasons to Buy:
- The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Cough in IPF Market.
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
- Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
- Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
- Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
- To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
- Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
Frequently Asked Questions:
1. What is the forecast period covered in the report?
The Cough in IPF Epidemiology and Market Insight report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of market dynamics and trends during this timeframe.
2. Who are the key players in the Cough in IPF market?
The Cough in IPF emerging market has few drugs. The major key players developing therapies for cough in IPF are Trevi Therapeutics, NeRRe Therapeutics, and others.
3. How is the market size estimated in the forecast report?
The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as prevalent cases, treatment costs, revenue generated, and market trends.
4. What is the key driver of the Cough in IPF market?
The increase in diagnosed prevalent cases of Cough in IPF and the launch of emerging therapies are attributed to be the key drivers for increasing Cough in IPF market.
5. What is the expected impact of emerging therapies or advancements in Cough in IPF treatment on the market?
Introducing new therapies, advancements in disease understanding and diagnostic techniques, and innovations in treatment approaches can significantly impact the Cough in IPF treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.
6. Does the report provide insights into the competitive landscape of the market?
The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Cough in IPF market.
Table of Contents
1. Key Insights
2. Report Introduction
3. Cough in Idiopathic pulmonary fibrosis (IPF) Market Overview at a Glance
- 3.1. Market Share (%) Distribution by Therapies of Cough in IPF in 2020
- 3.2. Market Share (%) Distribution by Therapies of Cough in IPF in 2034
4. Epidemiology and Market Methodology of Cough in IPF
5. Executive Summary of Cough in IPF
6. Key Events
7. Disease Background and Overview
- 7.1. Introduction
- 7.2. Signs and Symptoms of IPF
- 7.3. Cough in IPF
- 7.4. Pathophysiology of Chronic Cough
- 7.5. Pathophysiology of Cough in IPF
- 7.6. Mechanism of Cough in IPF
- 7.7. Comorbidities influencing cough in IPF
- 7.8. Diagnosis
- 7.8.1. Diagnostic Algorithm
- 7.8.2. Diagnostic Guideline
- 7.8.2.1. ATS-ERS-JRS-ALAT Recommendations Made for the Diagnosis of IPF
- 7.9. Treatment
- 7.9.1. Treatment of IPF
- 7.9.2. Treatment of Cough in IPF
- 7.9.3. Treatment Algorithm
- 7.9.4. Treatment Guidelines
- 7.9.4.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis (An Update of 2011 Clinical Practice Guideline)
- 7.9.4.2. French Practical Guidelines for the Diagnosis and Management of Idiopathic Pulmonary Fibrosis (2017)
- 7.9.4.3. NICE Guidelines on Idiopathic Pulmonary Fibrosis in Adults: Diagnosis and Management (2017)
- 7.10. General Approach to Cough Patients in IPF
8. Epidemiology and Patient Population
- 8.1. Key Findings
- 8.2. Assumption and Rationale of Cough in IPF: The 7MM
- 8.3. Total Diagnosed Prevalent Cases of Cough in IPF in the 7MM
- 8.4. The United States
- 8.4.1. Total Diagnosed Prevalent Cases of IPF in the US
- 8.4.2. Total Diagnosed Prevalent Cases of Cough in IPF in the US
- 8.5. EU4 and the UK
- 8.5.1. Germany
- 8.5.1.1. Total Diagnosed Prevalent Cases of IPF in Germany
- 8.5.1.2. Total Diagnosed Prevalent Cases of Cough in IPF in Germany
- 8.5.2. France
- 8.5.2.1. Total Diagnosed Prevalent Cases of IPF in France
- 8.5.2.2. Total Diagnosed Prevalent Cases of Cough in IPF in France
- 8.5.3. Italy
- 8.5.3.1. Total Diagnosed Prevalent Cases of IPF in Italy
- 8.5.3.2. Total Diagnosed Prevalent Cases of Cough in IPF in Italy
- 8.5.4. Spain
- 8.5.4.1. Total Diagnosed Prevalent Cases of IPF in Spain
- 8.5.4.2. Total Diagnosed Prevalent Cases of Cough in IPF in Spain
- 8.5.5. The United Kingdom
- 8.5.5.1. Total Diagnosed Prevalent Cases of IPF in the UK
- 8.5.5.2. Total Diagnosed Prevalent Cases of Cough in IPF in the UK
- 8.6. Japan
- 8.6.1. Total Diagnosed Prevalent Cases of IPF in Japan
- 8.6.2. Total Diagnosed Prevalent Cases of Cough in IPF in Japan
9. Patient Journey
10. Emerging Therapies
- 10.1. Key Cross Competition of Emerging Drugs
- 10.2. Orvepitant Maleate: NeRRe Therapeutics
- 10.2.1. Product Description
- 10.2.2. Other Development Activities
- 10.2.3. Clinical Development
- 10.2.4. Clinical Trial Information
- 10.2.5. Safety and Efficacy
- 10.2.6. Product Profile
- 10.2.7. Analysts' Views
- 10.3. Haduvio (Nalbuphine ER): Trevi Therapeutics
- 10.3.1. Product Description
- 10.3.2. Other Developmental Activities
- 10.3.3. Clinical Development
- 10.3.4. Clinical Trials Information
- 10.3.5. Safety and Efficacy
- 10.3.6. Product Profile
- 10.3.7. Analysts' Views
- 10.4. Ifenprodil (NP-120): Algernon Pharmaceuticals/Seyltx Inc.
- 10.4.1. Product Description
- 10.4.2. Other Developmental Activities
- 10.4.3. Clinical Development
- 10.4.4. Clinical Trials Information
- 10.4.5. Safety and Efficacy
- 10.4.6. Product Profile
- 10.4.7. Analysts' Views
- 10.5. ME-015 (Suplatast Tosilate): Melius Pharma AB
- 10.5.1. Product Description
- 10.5.2. Other Development Activities
- 10.5.3. Clinical Development
- 10.5.4. Clinical Trial Information
- 10.5.5. Product Profile
- 10.5.6. Analysts' Views
- 10.6. Sodium pyruvate (N115): Cellular Sciences/Emphycorp
- 10.6.1. Product Description
- 10.6.2. Other Development Activities
- 10.6.3. Clinical Development
- 10.6.4. Clinical Trial Information
- 10.6.5. Product Profile
- 10.6.6. Analysts' Views
11. Cough in IPF: Market Analysis
- 11.1. Key Findings
- 11.2. Key Market Forecast Assumptions
- 11.3. Market Outlook
- 11.4. Conjoint Analysis
- 11.5. Total Market Size of Cough in IPF in the 7MM
- 11.6. Market Size of Cough in IPF by Therapies in the 7MM
- 11.7. Market Size of Cough in IPF in the United States
- 11.7.1. Total Market Size of Cough in IPF
- 11.7.2. Market Size by Therapies of Cough in IPF in the United States
- 11.8. Market Size of Cough in IPF in EU4 and the UK
- 11.8.1. Germany
- 11.8.1.1. Total Market Size of Cough in IPF
- 11.8.1.2. Market Size by Therapies of Cough in IPF in Germany
- 11.8.2. France
- 11.8.2.1. Total Market Size of Cough in IPF
- 11.8.2.2. Market Size by Therapies of Cough in IPF in France
- 11.8.3. Italy
- 11.8.3.1. Total Market Size of Cough in IPF
- 11.8.3.2. Market Size by Therapies of Cough in IPF in Italy
- 11.8.4. Spain
- 11.8.4.1. Total Market Size of Cough in IPF
- 11.8.4.2. Market Size by Therapies of Cough in IPF in Spain
- 11.8.5. The United Kingdom
- 11.8.5.1. Total Market Size of Cough in IPF
- 11.8.5.2. Market Size by Therapies of Cough in IPF in the UK
- 11.9. Market Size of Cough in IPF in Japan
- 11.9.1. Total Market Size of Cough in IPF
- 11.9.2. Market Size by Therapies of Cough in IPF in Japan
12. Key Opinion Leaders' Views
13. SWOT Analysis
14. Unmet Needs
15. Market Access and Reimbursement
- 15.1. The United States
- 15.1.1. Center for Medicare and Medicaid Services (CMS)
- 15.2. In EU4 and the UK
- 15.2.1. Germany
- 15.2.2. France
- 15.2.3. Italy
- 15.2.4. Spain
- 15.2.5. The United Kingdom
- 15.3. Japan
16. Appendix
- 16.1. Bibliography
- 16.2. Acronyms and Abbreviations
- 16.3. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
